 |
Kirsten L. Greene, MD
Recent Publications |
Publications – 2007 |
 |
Garcia, M.M., S. Gulati, D. Liepmann, G.B.
Stackhouse, K. Greene, and M.L. Stoller, Traditional Foley
drainage systems--do they drain the bladder? J Urol, 2007.
177(1): p. 203-7; discussion 207. |
|
Greene, K.L., Does finasteride increase
PSA sensitivity? Abstr Hematol Oncol, 2007. 10(1): p. commentary. |
|
Greene, K.L., Prostate cancer: the problems
of overdiagnosis and overtreatment. Abstr Hematol Oncol,
2007. 10(1): p. commentary. |
|
| |
Publications – 2006 |
|
Greene, K.L., A. Berry, and B.R. Konety, Diagnostic
Utility of the ImmunoCyt/uCyt+ Test in Bladder Cancer. Rev Urol, 2006.
8(4): p. 190-7. |
|
Greene, K.L., E.P. Elkin, A. Karapetian,
J. Duchane, P.R. Carroll, and C.J. Kane, Prostate biopsy
tumor extent but not location predicts recurrence after
radical prostatectomy: results from CaPSURE. J Urol,
2006. 175(1): p. 125-9; discussion 129. |
|
Pookot, D., L.C. Li, Z.L. Tabatabai,
Y. Tanaka, K.L. Greene, and R. Dahiya, The E-cadherin
-160 C/A polymorphism and prostate cancer risk in white
and black American men. J Urol, 2006. 176(2): p. 793-6.
|
| |
Publications – 2005 |
|
Greene, K.L., F. Coakley, J. Kurhanewicz,
and P.R. Carroll, Endorectal MRI: when to consider in
PCa detection. Urol Times, 2005. |
|
Greene, K.L., M.R. Cooperberg, R.A. Hiatt,
and P.R. Carroll, Prostate cancer incidence, detection, and
treatment in 2005. San Francisco Medicine, 2005. |
|
Greene, K.L., J.E. Cowan, M.R.
Cooperberg, M.V. Meng, J. DuChane, and P.R. Carroll,
Who is the average patient presenting with prostate cancer?
Urology, 2005. 66(5 Suppl): p. 76-82. |
|
Greene, K.L. and C.J. Kane, Commentary
of histologic heterogeneity in multifocal prostatic adenocarcinoma:
implications for Gleason grading. Am J Urol Rev, 2005.
3: p. 301-3. |
|
Meng, M.V., K.L.
Greene, and
P.J. Turek, Surgery or assisted reproduction? A decision
analysis of treatment costs in male infertility. J Urol,
2005. 174(5): p. 1926-31. |
|
Zhao, H., H. Shiina, K.L.
Greene, L.C. Li, Y. Tanaka, H. Kishi, M. Igawa,
C.J. Kane, P. Carroll, and R. Dahiya, CpG methylation at promoter site -140 inactivates
TGFbeta2 receptor gene in prostate cancer. Cancer, 2005. 104(1): p. 44-52. |
| |
return
to top
|
|
|
|
|
|
